Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer
同种异体Vγ9Vδ2 T细胞免疫疗法表现出良好的临床安全性并延长晚期肺癌或肝癌患者的生存期
期刊:Cellular & Molecular Immunology
影响因子:21.8
doi:10.1038/s41423-020-0515-7
Yan Xu #, Zheng Xiang #, Mohammed Alnaggar #, Léonce Kouakanou #, Jiawei Li #, Junyi He #, Jiashuang Yang, Yi Hu, Yan Chen, Li Lin, Jianlei Hao, Jingxia Li, Jibing Chen, Man Li, Qingling Wu, Christian Peters, Qinghua Zhou, Jianshuang Li, Yingqing Liang, Xiaohua Wang, Baohui Han, Meili Ma, Dieter Kab
